# An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma

> **NCT03029780** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 104 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Opdivo
- **BIOLOGICAL:** Yervoy

## Key facts

- **NCT ID:** NCT03029780
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-16
- **Primary completion:** 2017-11-27
- **Final completion:** 2021-06-15
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2022-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03029780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03029780, "An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03029780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*